Knott, Simon R. V.
Wagenblast, Elvin
Khan, Showkhin
Kim, Sun Y.
Soto, Mar
Wagner, Michel
Turgeon, Marc-Olivier
Fish, Lisa
Erard, Nicolas
Gable, Annika L.
Maceli, Ashley R.
Dickopf, Steffen
Papachristou, Evangelia K.
D’Santos, Clive S.
Carey, Lisa A.
Wilkinson, John E.
Harrell, J. Chuck
Perou, Charles M.
Goodarzi, Hani
Poulogiannis, George
Hannon, Gregory J.
Article History
Received: 5 July 2016
Accepted: 15 December 2017
First Online: 7 February 2018
Change Date: 4 April 2018
Change Type: Erratum
Change Details: Please see accompanying Erratum (ExternalRef removed). In Fig. 3d, the blue bars should be ‘L-asparaginase’ rather than ‘L-asparagine; ‘orthotropic’ should be ‘orthotopic’ in the Extended Data Fig. 6 legend; and the legend to Supplementary Table 4 was repeated for Supplementary Table 5 in the HTML. These and some other minor wording changes have been corrected online.
Competing interests
: C.M.P. is an equity stock holder of BioClassifier LLC and University Genomics, and has filed a patent on the PAM50 subtyping assay. S.R.V.K., E.W., and G.J.H. are seeking patent protection on the manipulation of asparagine availability for patient benefit in the metastatic setting. The remaining authors declare no competing financial interests.